| For: | Qiu XX, Cheng SL, Liu YH, Li Y, Zhang R, Li NN, Li Z. Fecal microbiota transplantation for treatment of non-alcoholic fatty liver disease: Mechanism, clinical evidence, and prospect. World J Gastroenterol 2024; 30(8): 833-842 [PMID: 38516241 DOI: 10.3748/wjg.v30.i8.833] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v30/i8/833.htm |
| Number | Citing Articles |
| 1 |
Samradhi Singh, Mona Kriti, Roberto Catanzaro, Francesco Marotta, Mustafa Malvi, Ajay Jain, Vinod Verma, Ravinder Nagpal, Rajnarayan Tiwari, Manoj Kumar. Deciphering the Gut–Liver Axis: A Comprehensive Scientific Review of Non-Alcoholic Fatty Liver Disease. Livers 2024; 4(3) doi: 10.3390/livers4030032
|
| 2 |
Christopher Birigwa, Qiang Tong, Bing Qu, Teng Zuo, Wenzheng Yuan, Jing Xiong, Jianfei Luo. Gut microbiota-epigenetic interactions in systemic aging: mechanistic drivers for endocrine and reproductive network remodeling and therapeutic modulation. Frontiers in Aging 2026; 7 doi: 10.3389/fragi.2026.1826382
|
| 3 |
Jayeeta Bhowmick, Arka Bagchi. Live Biotherapeutics: Advancing Microbial Medicine. Progress in Molecular Biology and Translational Science 2026; 220 doi: 10.1016/bs.pmbts.2026.01.001
|
| 4 |
Wenchu Qian, Ling He, Chenxue Fu, Tiantian Zeng, Hanyu Wang, Haifang Li. Metabolic dysfunction-associated steatotic liver disease (MASLD): emerging insights into gut microbiota interactions and therapeutic perspectives. Exploration of Digestive Diseases 2025; 4 doi: 10.37349/edd.2025.100579
|
| 5 |
Roobee Garla, Naveen Kaushal, Tanvi Sharma. Toxins to treatments: Impact of environmental pollutants, gut microbiota, and natural compounds on non-alcoholic fatty liver disease progression. World Journal of Hepatology 2025; 17(8): 108772 doi: 10.4254/wjh.v17.i8.108772
|
| 6 |
Arun Kumar Mishra, Amrita Mishra, Akash Vikal, Harpreet Singh, Kamal Y Thajudeen, Gyas Khan, Mohammed Muqtader Ahmed. Fecal microbiota transplant and its usefulness in hepatic disorders: a systematic review. Therapeutic Advances in Gastroenterology 2026; 19 doi: 10.1177/17562848261452504
|
| 7 |
Xinxu Li, Qinghua Liu, Yajing Wang, Hongrui Zhang, Zhi Wu, Rui Fan, Yuyi Ma, Wei Gong, Xiaxi Li. Two modified colonoscopically guided fecal microbiota transplantation catheter placement methods: a retrospective study (with video). Frontiers in Medicine 2025; 12 doi: 10.3389/fmed.2025.1641325
|
| 8 |
Wesam Bahitham, Yusra Banoun, Mutep Aljahdali, Linah Aljahdali, Faisal M. Sanai, Consolato M. Sergi, Alexandre S. Rosado. Steatosis - Causes and Treatment. 2025; doi: 10.5772/intechopen.1012215
|
| 9 |
Giada Marroncini, Laura Naldi, Serena Martinelli, Amedeo Amedei. Gut–Liver–Pancreas Axis Crosstalk in Health and Disease: From the Role of Microbial Metabolites to Innovative Microbiota Manipulating Strategies. Biomedicines 2024; 12(7) doi: 10.3390/biomedicines12071398
|
| 10 |
Laura Martín Chaves, Fernando Rodríguez de Fonseca, Manuel F. Jiménez Navarro, Antonia Serrano Criado, Francisco Javier Pavón Morón. Pharmacological Targets in Metabolic Diseases. 2026; doi: 10.1016/B978-0-443-27370-4.00030-5
|
| 11 |
Carlo Acierno, Alfredo Caturano, Fannia Barletta, Luca Rinaldi, Ferdinando Carlo Sasso, Luigi Elio Adinolfi, Riccardo Nevola. Nutritional Interventions Targeting the Gut Microbiome in MASLD: From Prebiotics and Probiotics to Postbiotics and Fecal Microbiota Transplantation. Nutrients 2026; 18(11) doi: 10.3390/nu18111765
|
| 12 |
Luyu Wang, Hongtao Wang, Jian Wu, Changyi Ji, Ying Wang, Mengmeng Gu, Miaomiao Li, Hongwei Yang. Gut microbiota and metabolomics in metabolic dysfunction-associated fatty liver disease: interaction, mechanism, and therapeutic value. Frontiers in Cellular and Infection Microbiology 2025; 15 doi: 10.3389/fcimb.2025.1635638
|
| 13 |
Jiawang Wang, Zhongyu Wang, Yao Yu, Si Cheng, Jianping Wu. Advances in research on metabolic dysfunction-associated steatotic liver disease. Life Sciences 2025; 362 doi: 10.1016/j.lfs.2024.123362
|
| 14 |
Mahmoud Zhra, Muhammad Affan Elahi, Aamira Tariq, Ahmed Abu-Zaid, Ahmed Yaqinuddin. Sirtuins and Gut Microbiota: Dynamics in Health and a Journey from Metabolic Dysfunction to Hepatocellular Carcinoma. Cells 2025; 14(6) doi: 10.3390/cells14060466
|
| 15 |
Qing Zhou, Cuiting Yang, Mingyue Jia, Qingsong Qu, Xinhui Peng, Weishuo Ren, Guoqing Li, Yueyang Xie, Bingxuan Li, Xinyuan Shi. Gut Microbiota-Targeted Intervention of Hyperlipidemia Using Monascus-Fermented Ginseng. Pharmaceuticals 2025; 18(5) doi: 10.3390/ph18050661
|
| 16 |
DAI ISHIKAWA, XIAOCHEN ZHANG, AKIHITO NAGAHARA. Current Applications and Future Prospects of Fecal Microbiota Transplantation. Juntendo Medical Journal 2025; 71(2) doi: 10.14789/ejmj.JMJ24-0045-R
|
| 17 |
Bernd Schnabl, Christopher J. Damman, Rotonya M. Carr. Metabolic dysfunction–associated steatotic liver disease and the gut microbiome: pathogenic insights and therapeutic innovations. Journal of Clinical Investigation 2025; 135(7) doi: 10.1172/JCI186423
|
| 18 |
Dalia M. Miller, Kiana F. McCauley, Kimberly J. Dunham‐Snary. Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD): Mechanisms, Clinical Implications and Therapeutic Advances. Endocrinology, Diabetes & Metabolism 2025; 8(6) doi: 10.1002/edm2.70132
|
| 19 |
Chengyun Ma, Jing Wang, Xuanli Song, Xue Wang, Shuai Zong. Molecular mechanisms and clinical applications of gut microbiota-derived bioactive compounds in metabolic dysfunction-associated fatty liver disease. Frontiers in Immunology 2025; 16 doi: 10.3389/fimmu.2025.1682755
|